Literature DB >> 23300161

Burden of norovirus gastroenteritis in the ambulatory setting--United States, 2001-2009.

Paul A Gastañaduy1, Aron J Hall, Aaron T Curns, Umesh D Parashar, Benjamin A Lopman.   

Abstract

BACKGROUND: Gastroenteritis remains an important cause of morbidity in the United States. The burden of norovirus gastroenteritis in ambulatory US patients is not well understood.
METHODS: Cause-specified and cause-unspecified gastroenteritis emergency department (ED) and outpatient visits during July 2001-June 2009 were extracted from MarketScan insurance claim databases. By using cause-specified encounters, time-series regression models were fitted to predict the number of unspecified gastroenteritis visits due to specific pathogens other than norovirus. Model residuals were used to estimate norovirus visits. MarketScan rates were extrapolated to the US population to estimate national ambulatory visits.
RESULTS: During 2001-2009, the estimated annual mean rates of norovirus-associated ED and outpatient visits were 14 and 57 cases per 10 000 persons, respectively, across all ages. Rates for ages 0-4, 5-17, 18-64, and ≥65 years were 38, 10, 12, and 15 ED visits per 10 000 persons, respectively, and 233, 85, 35, and 54 outpatient visits per 10 000 persons, respectively. Norovirus was estimated to cause 13% of all gastroenteritis-associated ambulatory visits, with ~50% of such visits occurring during November-February. Nationally, norovirus contributed to approximately 400 000 ED visits and 1.7 million office visits annually, resulting in $284 million in healthcare charges.
CONCLUSIONS: Norovirus is a substantial cause of gastroenteritis in the ambulatory setting.

Entities:  

Mesh:

Year:  2013        PMID: 23300161     DOI: 10.1093/infdis/jis942

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  51 in total

1.  Nanobody-Mediated Neutralization Reveals an Achilles Heel for Norovirus.

Authors:  Anna D Koromyslova; Jessica M Devant; Turgay Kilic; Charles D Sabin; Virginie Malak; Grant S Hansman
Journal:  J Virol       Date:  2020-06-16       Impact factor: 5.103

2.  The phenomenon of summer diarrhea and its waning, 1910-1930.

Authors:  D Mark Anderson; Daniel I Rees; Tianyi Wang
Journal:  Explor Econ Hist       Date:  2020-06-19

3.  Understanding Toxoplasmosis in the United States Through "Large Data" Analyses.

Authors:  Joseph Lykins; Kanix Wang; Kelsey Wheeler; Fatima Clouser; Ashtyn Dixon; Kamal El Bissati; Ying Zhou; Christopher Lyttle; Andrey Rzhetsky; Rima McLeod
Journal:  Clin Infect Dis       Date:  2016-06-26       Impact factor: 9.079

Review 4.  Norovirus Illnesses in Children and Adolescents.

Authors:  Minesh P Shah; Aron J Hall
Journal:  Infect Dis Clin North Am       Date:  2018-03       Impact factor: 5.982

Review 5.  Economics and financing of vaccines for diarrheal diseases.

Authors:  Sarah M Bartsch; Bruce Y Lee
Journal:  Hum Vaccin Immunother       Date:  2014-04-22       Impact factor: 3.452

Review 6.  Involvement of Egyptian Foods in Foodborne Viral Illnesses: The Burden on Public Health and Related Environmental Risk Factors: An Overview.

Authors:  Hamada Aboubakr; Sagar Goyal
Journal:  Food Environ Virol       Date:  2019-09-27       Impact factor: 2.778

Review 7.  Treatment of norovirus infections: moving antivirals from the bench to the bedside.

Authors:  Stuart S Kaufman; Kim Y Green; Brent E Korba
Journal:  Antiviral Res       Date:  2014-02-25       Impact factor: 5.970

Review 8.  Norovirus immunology: Of mice and mechanisms.

Authors:  Kira L Newman; Juan S Leon
Journal:  Eur J Immunol       Date:  2015-08-25       Impact factor: 5.532

Review 9.  Epidemiology of human noroviruses and updates on vaccine development.

Authors:  Sasirekha Ramani; Robert L Atmar; Mary K Estes
Journal:  Curr Opin Gastroenterol       Date:  2014-01       Impact factor: 3.287

10.  Targeting pediatric versus elderly populations for norovirus vaccines: a model-based analysis of mass vaccination options.

Authors:  Molly K Steele; Justin V Remais; Manoj Gambhir; John W Glasser; Andreas Handel; Umesh D Parashar; Benjamin A Lopman
Journal:  Epidemics       Date:  2016-10-24       Impact factor: 4.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.